These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 11889200

  • 21. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
    Lugari R, Dell'Anna C, Ugolotti D, Dei Cas A, Barilli AL, Zandomeneghi R, Marani B, Iotti M, Orlandini A, Gnudi A.
    Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
    [Abstract] [Full Text] [Related]

  • 22. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 23. Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats.
    Park S, Hong SM, Sung SR.
    Life Sci; 2008 Feb 27; 82(9-10):503-11. PubMed ID: 18237751
    [Abstract] [Full Text] [Related]

  • 24. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD, Kim D, Weyer C.
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr 27; 2(1):63-82. PubMed ID: 12477297
    [Abstract] [Full Text] [Related]

  • 25. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
    Dupré J, Behme MT, McDonald TJ.
    J Clin Endocrinol Metab; 2004 Jul 27; 89(7):3469-73. PubMed ID: 15240633
    [Abstract] [Full Text] [Related]

  • 26. Effects of insulin on plasma magnesium in noninsulin-dependent diabetes mellitus: evidence for insulin resistance.
    Alzaid AA, Dinneen SF, Moyer TP, Rizza RA.
    J Clin Endocrinol Metab; 1995 Apr 27; 80(4):1376-81. PubMed ID: 7714113
    [Abstract] [Full Text] [Related]

  • 27. Reduced postprandial blood glucose levels in recently diagnosed non-insulin-dependent diabetics secondary to pharmacologically induced delayed gastric emptying.
    Phillips WT, Schwartz JG, McMahan CA.
    Dig Dis Sci; 1993 Jan 27; 38(1):51-8. PubMed ID: 8420760
    [Abstract] [Full Text] [Related]

  • 28. Changes in plasma growth hormone in diabetic and nondiabetic subjects during the glucose clamp.
    Sharp PS, Mohan V, Maneschi F, Vitelli F, Cloke HR, Burrin JM, Kohner EM.
    Metabolism; 1987 Jan 27; 36(1):71-5. PubMed ID: 2879210
    [Abstract] [Full Text] [Related]

  • 29. Exhaustion of blood glucose response and enhancement of insulin response after repeated glucagon injections in type-2 diabetes: potentiation by progressive hyperglycemia.
    Castillo MJ, Scheen AJ, Paolisso G, Lefebvre PJ.
    Ann Endocrinol (Paris); 1996 Jan 27; 57(5):395-402. PubMed ID: 8991103
    [Abstract] [Full Text] [Related]

  • 30. Exendin-4 partly ameliorates - hyperglycemia-mediated tissue damage in lungs of streptozotocin-induced diabetic mice.
    Oztay F, Sancar-Bas S, Gezginci-Oktayoglu S, Ercin M, Bolkent S.
    Peptides; 2018 Jan 27; 99():99-107. PubMed ID: 29225158
    [Abstract] [Full Text] [Related]

  • 31. Biological activity of EXf, a peptide analogue of exendin-4.
    Song GM, Huan Y, Sun SJ, Chen YT, Liu Q, Shen ZF.
    Eur J Pharmacol; 2010 Feb 25; 628(1-3):261-7. PubMed ID: 19919832
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.
    Gao W, Jusko WJ.
    J Pharmacol Exp Ther; 2011 Mar 25; 336(3):881-90. PubMed ID: 21156817
    [Abstract] [Full Text] [Related]

  • 33. Prednisolone enhances beta-cell function independently of ambient glycemic levels in type II diabetes.
    Hosker JP, Burnett MA, Matthews DR, Turner RC.
    Metabolism; 1993 Sep 25; 42(9):1116-20. PubMed ID: 8412763
    [Abstract] [Full Text] [Related]

  • 34. Rapid gastric emptying of a solid pancake meal in type II diabetic patients.
    Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT.
    Diabetes Care; 1996 May 25; 19(5):468-71. PubMed ID: 8732711
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Targeting postprandial hyperglycemia.
    Rendell MS, Jovanovic L.
    Metabolism; 2006 Sep 25; 55(9):1263-81. PubMed ID: 16919548
    [Abstract] [Full Text] [Related]

  • 38. [2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering prodrug.
    Shechter Y, Tsubery H, Fridkin M.
    Biochem Biophys Res Commun; 2003 May 30; 305(2):386-91. PubMed ID: 12745087
    [Abstract] [Full Text] [Related]

  • 39. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.
    Zhou J, Cai ZH, Li L, Kou C, Gao YF.
    Eur J Pharm Biopharm; 2009 Jun 30; 72(2):412-7. PubMed ID: 19462477
    [Abstract] [Full Text] [Related]

  • 40. Absence of exendin-4 effects on postprandial glucose and lipids in the Gila monster, Heloderma suspectum.
    Christel CM, Denardo DF.
    J Comp Physiol B; 2007 Jan 30; 177(1):129-34. PubMed ID: 16972064
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.